URI
URI Label
Revisions
Add to List
Edit Entry
Export:
XML
- May 2017 (4)
- April 2017 (1)
- February 2017 (2)
- December 2016 (3)
- October 2016 (2)
- September 2016 (6)
- August 2016 (26)
- July 2016 (26)
- June 2016 (1)
- April 2016 (27)
- March 2016 (6)
- February 2016 (2)
- January 2016 (11)
- December 2015 (2)
- November 2015 (8)
- October 2015 (14)
- September 2015 (11)
- August 2015 (19)
- July 2015 (18)
- June 2015 (10)
- May 2015 (22)
- April 2015 (22)
- March 2015 (1)
- January 2015 (11)
- December 2014 (10)
- November 2014 (18)
- October 2014 (11)
- September 2014 (33)
- August 2014 (58)
- July 2014 (46)
- June 2014 (41)
- May 2014 (35)
- April 2014 (40)
- March 2014 (25)
- February 2014 (44)
- January 2014 (13)
- December 2013 (13)
- November 2013 (19)
- October 2013 (19)
- September 2013 (3)
- Completed (60)
- Data Analysis (5)
- Data Required (5)
- Experiments (611)
- Predicting Metabolism (1)
- Strutures (1)
Show/Hide Keys
5-chloro-[1,2,4]triazolom4,3-a]pyrazine (500 mg, 3.24 mmol) was combined with N-bromosuccinimide (0.98 g, 3.56 mmol, 1.7 eq) in chloroform (25 mL) and refluxed from 4 pm. TLC showed new spots (plus two for SM) but still SM so left to stir o/n.
TLC:
N-bromosuccinamide purified prior to AEW 206-1 by recrystalliation in water:
20 g in 200 mL, heated to 95 ˚C until all solid dissolved and then left to cool at rt until white crystals formed. Then cooled to 0 ˚C for 30 minutes, filtered washed with cold water to yield a white solid (15 g).
Hazard and Risk Assessment:
See Synthesis of 3-bromo-5-chloro-[1,2,4]triazolo[4,3-a]pyrazine (TM 57-1)
Strings:
InChI=1S/C5H3ClN4/c6-4-1-7-2-5-9-8-3-10(4)5/h1-3H
to
InChI=1S/C5H2BrClN4/c6-5-10-9-4-2-8-1-3(7)11(4)5/h1-2H
ClC1=CN=CC2=NN=CN21
to
ClC1=CN=CC2=NN=C(Br)N21